Clinical Trials · NCT00517491

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Name: Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Withdrawn
Sponsor: Ipsen
Enrollment: 0
Start date: May 2008
Locations: 1 site, Mexico
Primary endpoint: GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg.

View Lanreotide compound reference